Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lentigo

ClinicalTrials.gov lists 36 trials for Lentigo or a narrower condition beneath it. Cryonove Pharma has the most among industry and government lead sponsors, with 3.

MeSH D007911 Skin and Connective Tissue Diseases C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 3 Phase 3 Phase 3 1 Phase 4 Phase 4 3 Not applicable Not applicable 12 Observational Observational 15 Phase 1 Phase 1 1 Phase 1/2 Phase 1/2 1 Phase 2 Phase 2 3 Phase 3 Phase 3 1 Phase 4 Phase 4 3 Not applicable Not applicable 12 Observational Observational 15

Trials per phase

13 of the 36 trials are tagged with Lentigo itself; the rest are tagged with a narrower condition beneath it.

Get the Lentigo report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lentigo trials start? (19)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 5

1995: 1 trials (Observational 1) 2002: 1 trials (Observational 1) 2006: 2 trials (Observational 1, Phase 1/2 1) 2008: 3 trials (Observational 1, Phase 2 2) 2010: 2 trials (Not applicable 1, Phase 2 1) 2011: 1 trials (Not applicable 1) 2012: 1 trials (Observational 1) 2013: 2 trials (Observational 1, Not applicable 1) 2014: 2 trials (Observational 1, Phase 3 1) 2015: 5 trials (Observational 1, Not applicable 3, Phase 1 1) 2016: 1 trials (Not applicable 1) 2017: 2 trials (Observational 2) 2018: 2 trials (Not applicable 1, Phase 4 1) 2019: 1 trials (Observational 1) 2021: 1 trials (Not applicable 1) 2022: 3 trials (Observational 3) 2023: 3 trials (Observational 1, Phase 4 2) 2024: 2 trials (Not applicable 2) 2025: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2025 1
2024 2
2023 3
2022 3
2021 1
2019 1
2018 2
2017 2
2016 1
2015 5

No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lentigo trials in? (7)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1
Phase 1/2 1
Phase 2 3
Phase 3 1
Phase 4 3
Not applicable 12
Observational 15

How many Lentigo trials are recruiting? (6)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 6
Active, not recruiting 1
Completed 19
Terminated 2
Withdrawn 2

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lentigo trials? (4)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Cryonove Pharma 3
Cutera Inc. 2
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) 1
Institut National de la Santé Et de la Recherche Médicale, France 1

Which drugs are being tested for Lentigo? (1)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
EVEROLIMUS 2

Interventions as named in the registry (14)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
15% Trichloroacetic acid + 3% glycolic acid 1
data collection 1
Secretin 1
CRYOTHERAPY 1
topical 0.05% Clobetasol propionate ointment 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which publications cover Lentigo? (23)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Facial skin characteristics and concerns in Indonesia: A cross-sectional observational study. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) 2022 Yes
A Randomized Controlled Trial on the Effectiveness of Epidermal Growth Factor-Containing Ointment on the Treatment of Solar Lentigines as Adjuvant Therapy. Medicina (Kaunas, Lithuania) 2021 Yes
Cryopeeling versus trichloroacetic acid peeling in the treatment of solar lentigines: Effect on epidermal Langerhans cells. Dermatologic therapy 2020 Yes
Development of a Pigmented Facial Lesion Scale Based on Darkness and Extent of Lesions in Older Veterans. The Journal of investigative dermatology 2019 Yes
Efficacy of D-pigment dermocosmetic lightening product for solar lentigo lesions of the hand: A randomized controlled trial. PloS one 2019 Yes

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.

Browse all condition evidence pages